Fluidigm Corp. (FLDM) Upgraded by Zacks Investment Research to “Hold”
According to Zacks, “Fluidigm Corporation operates as a biotech tools company that creates microfluidic-based chips and instrumentation for biological research. Products offered by the Company include BioMark HD System- a real time PCR; EP1 system for SNP genotyping; Access Array System-an Integrated Fluidic Circuit (IFC); TOPAZ system for protein crystallography; Dynamic Array integrated fluidic circuits (IFCs); and Access Array Assay Design Services. The Company’s products find its application in Gene Expression, Single-Cell Gene Expression, SNP Genotyping, Targeted Resequencing, Sample Quantitation, Copy Number Variation and Protein Crystallization. Fluidigm Corporation is based in San Francisco, California. “
Several other research analysts also recently commented on FLDM. Cantor Fitzgerald reissued a buy rating and issued a $9.00 target price (down from $11.00) on shares of Fluidigm Corp. in a report on Saturday, October 15th. Mizuho boosted their target price on Fluidigm Corp. from $11.00 to $12.00 and gave the stock a buy rating in a report on Friday, August 5th. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Fluidigm Corp. presently has a consensus rating of Buy and a consensus price target of $13.48.
Shares of Fluidigm Corp. (NASDAQ:FLDM) opened at 6.01 on Thursday. The firm’s market capitalization is $175.00 million. Fluidigm Corp. has a 12 month low of $4.31 and a 12 month high of $11.66. The stock’s 50 day moving average price is $5.80 and its 200-day moving average price is $8.45.
Fluidigm Corp. (NASDAQ:FLDM) last released its quarterly earnings data on Thursday, November 3rd. The company reported ($0.68) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.67) by $0.01. The company had revenue of $22.20 million for the quarter, compared to analyst estimates of $27.75 million. Fluidigm Corp. had a negative net margin of 64.65% and a negative return on equity of 59.15%. The firm’s revenue for the quarter was down 22.4% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.15) earnings per share. On average, equities analysts anticipate that Fluidigm Corp. will post ($2.59) earnings per share for the current fiscal year.
In related news, insider Levin Capital Strategies, L.P. acquired 159,200 shares of the company’s stock in a transaction that occurred on Monday, November 7th. The stock was purchased at an average price of $4.44 per share, for a total transaction of $706,848.00. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. 4.50% of the stock is currently owned by corporate insiders.
Hedge funds have recently modified their holdings of the stock. BlackRock Investment Management LLC boosted its stake in shares of Fluidigm Corp. by 6.2% in the second quarter. BlackRock Investment Management LLC now owns 109,868 shares of the company’s stock valued at $992,000 after buying an additional 6,429 shares during the last quarter. BlackRock Advisors LLC boosted its stake in shares of Fluidigm Corp. by 10.4% in the second quarter. BlackRock Advisors LLC now owns 14,529 shares of the company’s stock valued at $131,000 after buying an additional 1,373 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Fluidigm Corp. by 2.3% in the second quarter. Vanguard Group Inc. now owns 1,083,184 shares of the company’s stock valued at $9,781,000 after buying an additional 24,638 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of Fluidigm Corp. by 740.1% in the second quarter. Dimensional Fund Advisors LP now owns 134,871 shares of the company’s stock valued at $1,218,000 after buying an additional 118,816 shares during the last quarter. Finally, Neuberger Berman Group LLC boosted its stake in shares of Fluidigm Corp. by 1.5% in the second quarter. Neuberger Berman Group LLC now owns 926,340 shares of the company’s stock valued at $8,365,000 after buying an additional 13,547 shares during the last quarter. Institutional investors own 94.76% of the company’s stock.
Fluidigm Corp. Company Profile
Fluidigm Corporation creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company’s core microfluidics and mass cytometry technologies. The Company operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment.
Receive News & Stock Ratings for Fluidigm Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm Corp. and related stocks with our FREE daily email newsletter.